Hammersmith gets local connection rule
London local authority restricts social housing.
Yet another London borough authority has moved to stem the flow of people applying for social housing, with only those with a five-year connection to the local area permitted access to subsidised homes.
According to Hammersmith and Fulham council, new sanctions will be put into place in order to prioritise "local homes for local people", with a residency test being introduced as part of the application process.
The district follows an example set by Kensington and Chelsea, which last month stated that only vulnerable parties from local areas will be offered social tenancies and terminated lifetime contracts.
Prime minister David Cameron last week advocated the changes and told local authorities all over the country that they should be implementing the same measures in an attempt to control social housing waiting lists, which have been spinning out of control.
Councillor Andrew Johnson, the council's cabinet member for housing, said: “It cannot be fair for decent, honest people to sit on a council housing register for years and years and then see their housing dreams turn to dust when a new migrant, or someone from elsewhere in the country overtakes them in the queue."
The council stated that one person had been on the list for social housing for 36 years, while last year just 470 new lettings were made. It is hoped that adjustments to housing policy will avoid situations like these.
"Hammersmith and Fulham Council is … changing the rules so that local people with a five year connection to the borough come first," Mr Johnson concluded.
The local authority is currently constructing homes to add to its extensive portfolio of social housing, having started up its own company last year to deal with an influx of applications for affordable housing.
It hopes to have completed 500 low-cost units within the next ten years.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance